Startup Scout 12 Jul 2019 This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer Next time you travel to Barcelona, Spain, check out Aromics, a biotech that is using genomics and proteomics to develop treatments for cancers such as malignant mesothelioma, which can be caused by asbestos. Mission: To use omics technology to treat drug-resistant cancers, as well as to identify cancer biomarkers that could improve monitoring in clinical […] July 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2019 Bayer Launches Israeli Company to Develop Viruses Against Crop Disease Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […] July 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2019 French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae The French biotech Microphyt has raised €28.5M ($32M) to commercialize nutritional and cosmetic products harvested from microalgae. Over the next 18 months, Microphyt will use the money to ramp up its workforce and industrial capacity in preparation for pushing its microalgal food ingredients and cosmetics to market. The company is developing technology to overcome a […] July 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2019 French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A The French biotech Osivax has advanced in the race to develop a universal flu vaccine, raising €8M to achieve clinical proof-of-concept. Osivax will use most of the funding to progress its lead candidate vaccine towards market approval. Targeting all strains of influenza A viruses, the vaccine is currently in a phase I trial, with results […] July 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2019 Anti-Aging Gene Therapy Treats Cardiovascular Disease in Mice A research group in Italy has reduced cardiovascular disease in mice by expressing an anti-aging gene often seen in centenarians. This could one day lead to a gene therapy treating the same condition in humans. Centenarians have long lives thanks to a mix of their environment, lifestyle, and their genes. In the past, researchers at […] July 10, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2019 Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […] July 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2019 BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […] July 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2019 Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […] July 8, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2019 European Biotech: The Insider View How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […] July 7, 2019 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2019 French Biotech’s Plant Extract Cuts Blood Glucose in Prediabetic People A plant extract developed by the French biotech Valbiotis is the first food supplement to reduce blood glucose levels in people at high risk of developing type 2 diabetes. In a phase IIa trial, Valbiotis compared its food supplement with a placebo in 51 people with prediabetes. After six months, the supplement had reduced blood […] July 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 5 Jul 2019 This Biotech Helps the Immune System to Infiltrate and Destroy Tumors The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […] July 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2019 Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series A funds will be used to launch the clinical development of Citryll’s lead antibody, which is designed to treat the autoimmune condition lupus. The money […] July 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email